Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
Substantial doubt about the company's ability to continue as a going concern.
“Due in large part to the ongoing clinical trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Earnings call · FY2025 Q4
Executive readout · one minute
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
Filed Jan 5, 2026 · complete as-filed document
SEC periodic report
Filed Mar 26, 2026 · complete as-filed document